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Review of health-related quality of life data in multiple myeloma
patients treated with novel agents
P Sonneveld1,7, SG Verelst1,7, P Lewis2, V Gray-Schopfer3, A Hutchings4, A Nixon5 and MT Petrucci6
In multiple myeloma (MM), health-related quality of life (HRQoL) data is becoming increasingly important, owing to improved
survival outcomes and the impact of treatment-related toxicity on HRQoL. Researchers are more frequently including HRQoL
assessments in clinical trials, but analysis and reporting of this data has not been consistent. A systematic literature review assessed
the effect of novel agents (thalidomide, bortezomib and lenalidomide) on HRQoL in MM patients, and evaluated the subsequent
reporting of these HRQoL results. A relatively small body of literature addresses HRQoL data in MM patients treated with novel MM
therapeutic agents: 9 manuscripts and 15 conference proceedings. The literature demonstrates the complementary value of HRQoL
when assessing clinical response, progression, overall survival and toxicity. However, weaknesses and inconsistencies in analysis
and presentation of HRQoL data were observed, often complicating interpretation of the impact of treatment on HRQoL in MM.
Further evaluation of HRQoL in MM patients treated with novel agents is required in larger cohorts, and ideally in head-to-head
comparative studies. Additionally, the development of standardised MM-speciﬁc best practice guidelines in HRQoL data collection
and analysis is recommended. These would ensure that future data are more useful in guiding predictive models and clinical
decisions.
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INTRODUCTION
Multiple myeloma (MM), a clonal proliferation of plasma cells, is an
incurable disease in which patients often have pronounced
symptoms and substantially reduced health-related quality of life
(HRQoL).1 Eighty percent of patients experience skeletal
destruction,2,3 B73% will have anaemia at diagnosis4 and
B30% of patients present with renal insufﬁciency.5 Impaired
immune function is also an important characteristic of the disease
that leads to severe infections.6,7 Treatment of MM has improved
substantially in recent years, leading to prolonged overall survival
upon introduction of high-dose chemotherapy combined with
autologous stem cell transplantation (ASCT) and use of agents
such as thalidomide, bortezomib and lenalidomide.8,9 Despite
therapeutic advances, survival prognosis remains poor, with a
5-year relative survival rate of 35–37% in newly diagnosed multiple
myeloma (NDMM) patients, although substantial improvements
have been observed in patients up to 59 years of age. Survival
rates and prognoses decrease with patient age (X70 years).10–13
Bortezomib monotherapy and lenalidomide in combination with
dexamethasone are both licensed for the treatment of MM
patients who have undergone at least one prior therapy. Both
therapies have shown statistically and clinically signiﬁcant
improvements over dexamethasone alone in terms of response
rates, time to progression and overall survival.14–18 High-dose
chemotherapy with ASCT is the standard of care for transplant-
eligible, NDMM patients, typically those younger than 65 years of
age.19,20 Novel agents, such as thalidomide, lenalidomide and
bortezomib, ﬁgure prominently in the treatment of these NDMM
patients, and are being used in combination with vincristine,
adriamycin and/or dexamethasone/low-dose dexamethasone.21–23
These novel agents have also shown efﬁcacy as maintenance
treatment post-ASCT, although no drug is currently licensed in this
indication.22,24–27
Novel agents have also changed MM management in elderly
patients not eligible for ASCT.28 Combinations of melphalan,
prednisone and thalidomide (MPT)29–31 and of bortezomib,
melphalan and prednisone (VMP)32,33 have shown improved
progression-free survival and overall survival compared with
melphalan and prednisone (MP) alone. Both MPT and VMP
combinations are licensed in Europe for treatment of non-ASCT-
eligible NDMM patients and are the current standards of care for
elderly patients.20 Data also support the role of the combination
of melphalan, prednisone and lenalidomide followed
by lenalidomide maintenance (MPR-R) in the treatment of
elderly non-ASCT-eligible patients,34,35 although it is not
currently licensed.
While many of these novel agents have demonstrated
improved survival rates, they are also associated with some
adverse events (AEs), which can impact on patient HRQoL.36,37 In a
prospective study of 154 MM patients in the United Kingdom and
Germany, the impact of speciﬁc MM symptoms and AEs were
correlated with HRQoL scores after adjusting for the level of
disease severity. While severe bone pain and being severely
symptomatic had the most deleterious effect on patient HRQoL,
patients who were receiving MM treatment also reported lower
HRQoL, related to treatment toxicity.38 It is therefore important to
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fully understand the effects of treatments on patients’ HRQoL. The
increasing number of trials evaluating HRQoL in haematological
malignancies is a testament to the growing importance of patient-
reported outcomes.39–42
The aims of MM treatment are to control disease, prolong
survival and maximise patient wellbeing. HRQoL instruments can
be incorporated into clinical studies in order to get a more
comprehensive evaluation of treatment outcomes. However, the
value of HRQoL data in guiding clinical practice depends upon the
quality and comparability of these data.
Careful consideration should be given to the study design,
including HRQoL instrument selection, a statistical analysis plan
and the reporting of results.43,44 Indeed, accumulating evidence
indicate that published clinical trials assessing HRQoL have failed
to meet good scientiﬁc standards of reporting, and internationally
agreed upon standards have been called for.45,46
HRQoL data are now routinely captured in studies of new
treatments for MM. The objective of this publication was to review
available HRQoL data for the newer MM treatments and to
critically evaluate the standards of HRQoL data collection, analysis
and reporting. It is hoped that our review will help guide the
standardisation of HRQoL data collection, analysis and reporting,
to work towards either internationally agreed upon guidelines or
incorporation into future MM studies.
MATERIALS AND METHODS
A systematic literature review was performed to identify relevant articles
pertaining to the treatment-related HRQoL impact of thalidomide,
bortezomib or lenalidomide in MM patients. The following electronic
bibliographic and treatment guideline databases were searched: EMBASE,
PubMed, National Guideline Clearinghouse Cochrane Database of
Systematic Reviews, ClinicalTrials.gov and ClinicalStudyResults.org clinical
trial registers (January 2000 through 31 December 2012). Supplementary
searches included oncology and haematology conference proceedings
(European Hematology Association (EHA), American Society of Clinical
Oncology (ASCO), American Society of Hematology (ASH) and International
Myeloma Working Group (IMW)), grey literature and reference lists of key
papers. The search was restricted to documentation published in human
subjects. All interventional study designs involving patients with MM were
included, with the exception of case studies. Greater emphasis was placed
on randomised controlled trial (RCT) data. Review articles were excluded.
The literature search identiﬁed 420 potential publications. After the
abstracts for each study were reviewed against the inclusion/exclusion
criteria by two independent contributors, 9 manuscripts and 15 conference
proceedings (7 ASH, 5 EHA, 2 ASCO and 1 IMW) were considered relevant.
Reasons for exclusion included insufﬁcient HRQoL data and non-relevant
clinical intervention. The relatively limited amount of retrieved literature
was anticipated, given that these therapies are fairly recent and are
supported by a limited number of clinical trials that have derived HRQoL
analysis. The most frequently used HRQoL instruments in the MM studies
included in the current review are brieﬂy outlined in Box 1 and Table 1.
Studies reporting on HRQoL in MM patients treated with
thalidomide
Two clinical trials evaluating MPT vs MP,47–49 and one study evaluating
dexamethasone combined with thalidomide (TD) or bortezomib (VD)50
were retrieved. Key HRQoL results from these trials are summarised in
Table 2.
HRQoL data from the HOVON49 phase III study. The HOVON49 rando-
mised, multi-centre, open-label, phase III trial compared MP (n¼ 168) with
MPT (n¼ 165) followed by thalidomide maintenance in elderly (465 years)
NDMM patients.51 The MPT regimen has become a standard treatment in
this population, based on data from ﬁve RCTs.29,30,48,51–54 Eight treatment
cycles were planned in the HOVON49 study. Patients who completed the
planned MPT cycles received thalidomide maintenance therapy until
progression, whereas patients in the MP arm received no maintenance.
After disease progression (PD) or no response, salvage therapy was given
according to the physician’s choice. HRQoL was evaluated as a secondary
end point in the study using the QLQ-C30 and QLQ-MY24 questionnaires
(Table 1). HRQoL was measured at ﬁve pre-determined time points during
the course of treatment.47
Both treatment arms resulted in improved overall Global Health Status
(GHS)/Global QoL, Fatigue, Side Effects of Treatment, Pain, Insomnia and
Appetite Loss scores, although differences in favour of MPT were observed
for these latter three scores. However, MPT was associated with a
signiﬁcant increase in paraesthesia from post-induction onwards,
consistent with a cumulative dose-dependent effect of thalidomide.51,55
The higher incidence of constipation and paraesthesia with MPT vs MP was
Box 1. HRQoL in MM and overview of commonly used
HRQoL instruments
 QLQ-C30: 30-item, self-administered HRQoL patient
questionnaire is designed for use in cancer patients.
It has a one-week recall period and is composed of
multi-item and single scales, including ﬁve functional
scales (Physical, Role, Emotional, Social, and Cognitive
Functioning), three symptom scales (Fatigue, Nausea/
Vomiting and Pain) and a Global Health Status (GHS)/
Quality of Life (QoL) scale. Single items include
Dyspnoea, Insomnia, Appetite Loss, Constipation,
Diarrhoea and Financial Difﬁculties. The QLQ-C30 has
demonstrated good psychometric properties in solid
tumours85,86 and reliability and validity in MM
patients87–90. The Minimal Important Difference (MID),
deﬁned as the smallest change in an HRQoL score
considered important to patients that would lead the
patient or clinician to consider a change in therapy,91
has been estimated for QLQ-C30 in MM patients.56
 QLQ-MY24 and QLQ-MY20: QLQ-MY24 was developed as
an addition to QLQ-C30 for speciﬁc use in MM.92,93 The
QLQ-MY24 was reﬁned to 20 items (QLQ-MY20). It has a
1-week recall period and addresses four important
domains in MM: Disease Symptoms, Side Effects of
Treatment, Body Image and Future Perspectives. The
psychometrics, including reliability and validity of
QLQ-MY20, in MM have been published.92
 QLQ-CIPN20: the reliability, validity and responsiveness
of the 20-item QLQ-CIPN20 instrument for patient-
reported chemotherapy-induced peripheral neuropathy
(CIPN) is currently being investigated in a wide range of
oncology patient populations. The instrument has three
subscales: a sensory, motor and autonomic subscale.94
 FACT-Multiple Myeloma: a 14-item disease-speciﬁc FACT-
MM HRQoL measure has been developed and has
demonstrated acceptable psychometric properties.95,96
 FACIT-Fatigue: bolt-on module to the base FACT-General
(FACT-G) HRQoL questionnaire, a 27-item instrument
measuring Well being (Physical, Social/Family, Emotional
and Functional), with a recall period of 1 week.97 The
MID has been estimated and veriﬁed in a group of
mixed diagnosis cancer patients.98 No reliability, validity
or other psychometric properties of the FACIT-Fatigue
speciﬁc to MM have been described.
 FACT-NTx: another FACT-G bolt-on module with addi-
tional neurotoxicity parameters. It has demonstrated
good psychometric properties in women with ovarian
cancer,99 but has only been used in a limited number of
MM studies, similarly to FACIT-Fatigue.
 EQ-5D: standardised generic HRQoL questionnaire that
can be converted into a ‘health utility’ score ques-
tionnaire used to measure health outcomes. The MID
has recently been described for EQ-5D in MM
patients.100
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not reﬂected in overall HRQoL. No unfavourable overall difference in self-
reported side effects between the two arms was observed during the study
protocol. Verelst et al. explored whether the improvement in HRQoL from
baseline seen was clinically signiﬁcant. The MM-speciﬁc minimally
important difference (MID) for the QLQ-C30 was deﬁned as a difference
of 6–17 points, as estimated by Kvam et al.56 MID is deﬁned as the smallest
change in an HRQoL score considered important to patients that would
lead the patient or clinician to consider a change in therapy. It was
concluded that a clinically signiﬁcant difference was observed for GHS/
QoL, Role Functioning, Emotional Functioning, Social Functioning, Fatigue
and Pain at the end of post-induction (18 months, during the period
following the ﬁrst week after induction treatment until the start of the next
treatment off protocol) in favour of MPT-treated patients compared with
MP. This prospective study showed that the higher frequency of toxicity
associated with MPT did not translate into a negative effect on HRQoL and
that patients on MPT have a better outlook. The authors concluded that
MPT improved clinical outcome with no reduction in HRQoL (Table 2).
Critical review of HOVON49 HRQoL data. The use of a prospective design
allowed the evaluation of HRQoL at different time points and treatment
stages, with repeated measurements, owing to a linear mixed statistical
model, which took into account correlation between measurements from
the same patients. The model allowed a clear distinction between
differences in the two randomisation arms at baseline and those possibly
caused by additional thalidomide treatment. Thus, differences present at
baseline did not generate signiﬁcant interaction with time.
The HRQoL questionnaires were ﬁrst completed by patients before
treatment but after randomisation. The HOVON49 study authors hypothe-
sised that anticipation of receiving beneﬁcial treatment may have biased
HRQoL reporting. As the study was open-labelled, patients in the MPT arm
may score better at baseline. Indeed, at baseline, the MPT cohort had
statistically signiﬁcantly higher HRQoL scores for QLQ-C30 Emotional
Functioning and GHS/QoL subscales, and for QLQ-MY24 Future Perspec-
tives and Social Support subscales.
The quality of the data may be diminished by the open-label study
design, which risks incorporating bias, and is further limited by the fact
that not all HOVON49 trial patients participated in the HRQoL survey.
Compliance rates with completing questionnaires at different study time
points were not reported. Furthermore, although patients were evaluated
at pre-determined treatment time points, not all patients completed
questionnaires at the same time. Finally, although clinically meaningful
MID thresholds for MM were applied,56 within-trial and domain-speciﬁc
distribution-based MID estimates would have provided additional insight
into the clinically meaningful changes.43
HRQoL data from the Nordic Myeloma Study Group (NMSG). Waage et al.
conducted a double-blind, placebo-controlled study in untreated elderly
NDMM patients randomised to receive MPT (n¼ 182) or MP (n¼ 175)
(Table 2). HRQoL was assessed as a secondary end point. Generalised
estimating equations were applied, making full use of repeated quarterly
measures (Table 1) and allowing for within-patient correlations over
successive time points. Analyses were carried out using the observed
values of QLQ-C30 scores, including baseline (pre-randomisation) QLQ-C30
scores as covariates.48,49
In both treatment arms, HRQoL improved after treatment initiation. Little
difference was detected between treatment arms, although signiﬁcant
differences were observed in favour of MP in Physical Functioning
(P¼ 0.025) and Social Functioning (P¼ 0.013). There was a marked increase
in the Constipation score among patients in the MPT arm (Po0.001), and a
corresponding tendency to an increase (HRQoL worsening) in the
Diarrhoea score in MP patients (P¼ 0.002). Compliance with completing
the QLQ-C30 questionnaire was 82% in the MPT arm and 90% in the MP
arm at 3 months, and 50% and 62% at 12 months, respectively.
Critical review of NMSG HRQoL data. The main advantage of this HRQoL
data is the study’s double-blind, placebo-controlled design, which
eliminates reporting bias. Multiple imputation of missing data values
showed no evidence of bias in the comparison of treatments. However, the
HRQoL data were substantially weakened in this double-blind trial by poor
compliance in questionnaire completion as the study progressed.
HRQoL data from the NMSG (Hjorth et al.). Thalidomide- and bortezomib-
naive patients with melphalan-refractory myeloma were randomly
assigned to low-dose TD (n¼ 67) vs VD (n¼ 64) in an open phase III
randomised multi-centre trial conducted by Hjorth et al. HRQoL was
assessed as a secondary end point, measured by the QLQ-C30
questionnaire (Tables 1 and 2). The questionnaire was completed by
96% of patients still alive at 6 weeks, 90% at 12 weeks and by 76% patients
at 6 months. No HRQoL improvement over time was observed for either
treatment group. No between-group differences were noted, except that
Table 1. HRQoL instruments used in MM studies
Trial (Reference) HRQoL instruments Timing of HRQoL assessments
Thalidomide
HOVON4947 QLQ-C30, QLQ-MY24 Measurements for QoL were collected at study entry, after cycle 3 (B3 months after
the start of cycle 1), after cycle 8 (B9 months after the start of cycle 1), at 12 and
18 months after the start of cycle 1
Waage et al.;
Guldbrandsen et al.48,49
QLQ-C30 The questionnaires were completed at inclusion and later posted to patients every
third month throughout the study
Hjorth et al.50 QLQ-C30 Questionnaires were completed before randomisation (before start of treatment)
and mailed to the patients after 6 and 12 weeks, after 6 months and every 6 months
thereafter until the end of the study
Bortezomib




Patients completed the questionnaires during screening, on day 1 of cycles 3, 5
and 7 of treatment, as well as at the end of the study
VISTA62,66,67 QLQ-C30 Patients completed the questionnaire at screening, on day 1 of each cycle during
the treatment phase and every 8 weeks until progression during follow-up
UPFRONT68–71 QLQ-C30 Patients completed the questionnaire before dosing on day 1 of cycle 1 (baseline),
before dosing on day 1 of every odd-numbered cycle, at the end-of-treatment visit
and every 12 weeks thereafter
Lenalidomide
MM-01573–76 QLQ-C30, QLQ-MY20 Questionnaires were completed at baseline, at the beginning of every third cycle
(cycles 4, 7, 10, 13 and 16), at study discontinuation and every 6 months in
long-term follow-up
MM-01877–79 QLQ-C30, QLQ MY20 Questionnaires were completed at baseline and at week 24
Abbreviations: HRQoL, health-related quality of life; MM, multiple myeloma.
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the Fatigue score was worse at 12 weeks (P¼ 0.04) in the VD group.
A higher Sleep Disturbances score was also noted in the VD group at
6 (P¼ 0.06) and 12 weeks (Po0.01), potentially related to neurotoxicity.
Critical review of NMSG HRQoL data (Hjorth et al.). The trial was
prematurely closed because of low accrual and was therefore weakened
by the low number of recruited patients. However, it remains pertinent, as
no other randomised data comparing thalidomide with bortezomib are
available.
All domains of the QLQ-C30 were collected and reported for all time
points, and all patients were included in the analysis in accordance with
intention to treat principle. However, there was relatively little description
of how HRQoL data were analysed, and it was not possible to infer how
missing data were treated.
Clinically meaningful thresholds were used in interpreting HRQoL
results, but a single MID of X10 points was used across all domains.57
Compliance in questionnaire completion was high. The HRQoL
questionnaires were ﬁrst completed before randomisation, thus
eliminating bias in HRQoL reporting at that time point. As in the
HOVON49 trial, the quality of the data is diminished by the open-label
design.
Studies reporting on HRQoL in MM patients treated with
bortezomib
Three publications reported HRQoL results for bortezomib treatment in the
relapsed/refractory multiple myeloma (RRMM) setting,58–60 covering the
APEX phase III and SUMMIT phase II trials.17,61 The phase III VISTA trial
reported HRQoL results for bortezomib treatment in elderly NDMM
patients.62 These publications were also discussed in earlier conference
proceedings,63–67 which also reported on the UPFRONT clinical trial in NDMM
patients.68–71 Key HRQoL results from these trials are summarised in Table 3.
HRQoL data from the APEX phase III trial. The APEX study was a
randomised, open-label trial comparing bortezomib (n¼ 296) with high-
dose dexamethasone (n¼ 302) in patients with relapsed MM, evaluated
with the QLQ-C30 and the FACT-Ntx questionnaires (Table 1). Assessment
of HRQoL was included as a pre-speciﬁed exploratory efﬁcacy objective.
The APEX trial was stopped early owing to a 29% vs 52% progression rate
in favour of bortezomib. In the bortezomib arm, 9% completed all
protocol-speciﬁed treatment, while in the dexamethasone arm, 5%
completed treatment.60 HRQoL assessments were discontinued when
patients stopped protocol treatment, leading to a high amount of missing
data.
At baseline, mean QLQ-C30 scores were signiﬁcantly better for
bortezomib vs dexamethasone in Emotional Functioning, Fatigue, Sleep
and Diarrhoea. Baseline FACT-Ntx scores were comparable across groups.
HRQoL scores during the 42 weeks of the trial were analysed using
generalised estimating equation analysis of covariance.72 QLQ-C30 analysis
found signiﬁcantly better HRQoL in the bortezomib group vs
dexamethasone, although a declining trend in mean GHS score was
observed in both arms (Table 3). The component scores for Physical, Role,
Cognitive and Emotional Functioning, and the symptom scores for
Dyspnoea and Sleep were signiﬁcantly better for the bortezomib
group. For the overall FACT-Ntx score, statistically signiﬁcant differences
favouring the bortezomib arm were reported, when missing data
due to patient death were imputed as worst possible score (zero), but
this difference became nonsigniﬁcant when treated as withdrawals/
missing data.
Critical review of APEX HRQoL data. The APEX trial was an open-label
randomised study. This landmark trial reported an HRQoL beneﬁt of
bortezomib over dexamethasone. There were some differences in the two
treatment arms at baseline: the bortezomib group reported better
functioning and fewer symptoms than the dexamethasone group. These
differences may be owing to chance, as the treatment arm was randomly
assigned, HRQoL assessments were made before therapy started and the
two groups were balanced for clinical characteristics. In responding
patients, HRQoL changes from baseline were similar for most domains,
except for better sleep and more neurotoxicity in bortezomib-treated
patients, and less nausea and anorexia in the high-dose dexamethasone-
treated group, consistent with clinical experience. The analysis may have
been more robust if the HRQoL changes over time had been taken into
account. The number of patients excluded from the HRQoL analyses was
disclosed (n¼ 45, because a baseline assessment was missing or because
only a baseline assessment was completed). The study also acknowledged
Table 2. Key results from thalidomide clinical trials reporting HRQoL data
Trial/references Trial design Key HRQoL results
Thalidomide
HOVON4947 Prospective HRQoL study to assess the impact
of thalidomide on HRQoL. Standard MP (n¼ 168)
vs MPT followed by Thal maintenance (n¼ 165) in
elderly (465 years) NDMM patients
Physical Function and Constipation (significant) showed an
improvement during induction in favour of the MP arm
During Thal maintenance, paraesthesia was significantly
higher in the MPT arm, and a trend towards improved Pain,
Insomnia, Appetite Loss and the QLQ-MY24 item sick scores
was observed
The GHS/Global HRQoL scale showed a significant time
trend towards more favourable mean values during protocol
treatment without differences between MP and MPT
For the QLQ-C30 subscales, Emotional Functioning and
Future Perspectives, a difference in favour of the MPT arm
from the start of treatment was observed, with no significant
‘time arm’ interaction, indicating a persistent better patient
perspective with MPT treatment
Waage et al.;
Guldbrandsen et al.48,49
Phase III randomised, double-blind,
placebo-controlled study in untreated elderly
NDMM patients to compare MPT (n¼ 182) vs MP
(n¼ 175)
Overall, HRQoL outcomes improved equally in both arms,
apart from markedly increased Constipation in the MPT arm
Hjorth et al.50 Open phase III randomised multi-centre trial
to compare TD (n¼ 67) vs VD (n¼ 64) in
melphalan-refractory myeloma patients
No differences were noted for Physical Functioning, Pain and
GHS/QoL. Fatigue and Sleep Disturbances were more
prevalent in the VD group. The Fatigue score for the VD
group was worse at 12 weeks, with a score difference of 10
(P¼ 0.04). The difference from the time of randomisation in
score for Sleep Disturbances in the VD group reached
statistical significance at 12 weeks (Po0.01)
Abbreviations: GHS, Global Health Status; HRQoL, health-related quality of life; MP, melphalan and prednisone; MPT, melphalan, prednisone and thalidomide;
NDMM, newly diagnosed multiple myeloma; Thal, thalidomide; TD, thalidomide and dexamethasone; VD, bortezomib and dexamethasone.
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that missing data increased with time, owing to AEs that led to
discontinuation, PD, premature termination of the dexamethasone arm
of the study and death. Although the number of patients completing
treatment cycles was reported, the study did not specify compliance rates.
The study assessed the change in HRQoL scores over time by comparing
the change in scores according to clinical response between baseline and
the best clinical response (best endpoint).60 The choice of ‘best endpoint’
for HRQoL analysis rather than a combination of data points throughout
the trial could be considered selective. This approach may introduce bias,
as AEs or symptoms occurring at other time points would be discounted.
Furthermore, the statistical analysis plan for the evaluation of the HRQoL
data pre-speciﬁed four analytical methods, including two that included
and two that excluded multiple data imputations, each combined with
deaths assigned a zero value or deaths treated as withdrawals. Details on
GHS/QoL data were primarily reported based on the method with no
multiple data imputation, and deaths assigned a zero value, reporting an
HRQoL beneﬁt for bortezomib. No statistically signiﬁcant differences in
GHS/QoL between bortezomib and dexamethasone were observed with
multiple data imputations and deaths treated as withdrawals.60 The way in
which deaths were treated had an important impact on data
interpretation. As acknowledged by the authors, this approach likely
biased the results in favour of bortezomib, given the signiﬁcant survival
beneﬁt seen in the trial.16
HRQoL data from the SUMMIT phase II trial. SUMMIT was an open-label,
single-arm trial of bortezomib in 202 patients with RRMM after at least two
previous treatments. The study design was described previously.61 During
the ﬁrst two cycles, all patients received bortezomib, and dexamethasone
could be added for patients with stable disease or PD after four cycles. The
study reported rates of 96–97% HRQoL completion at baseline and
76–77% at close-out.
The trial analysed HRQoL results (Tables 1 and 3) reported by clinical
response in order to predict the prognostic value of HRQoL for survival in
MM.58,59
For the total patient population with available clinical response
information (n¼ 151) and available HRQoL data (n¼ 144), there was a
positive change between baseline and best end point. Changes in HRQoL
scores showed statistically signiﬁcant differences between response
groups with HRQoL improvement in responding patients (with complete
response (CR) or partial response), overall stable scores in patients with
minor response or stable disease, and overall decreased scores in PD
patients.58
The value of baseline HRQoL data in predicting mortality during
treatment was analysed through univariate and multivariate logistic
regression and by partial least squares regression. Fifteen baseline
HRQoL parameters were signiﬁcant in predicting mortality during
treatment when univariate logistic regression was used, but only the
QLQ-C30 fatigue and physical subscores were signiﬁcant predictors of
survival in a subsequent multivariate regression (Table 3).59
Critical review of SUMMIT HRQoL data. As a treatment comparison arm
was not included, the impact of treatment on HRQoL changes is difﬁcult to
Table 3. Key results from bortezomib clinical trials reporting HRQoL data
Trial/references Trial design Key HRQoL results
Bortezomib
APEX60,65 Prospective, open-label, randomised, phase III trial of
bortezomib (n¼ 296) vs Dex (n¼ 302) in patients with
relapsed MM
Bortezomib was associated with significantly better HRQoL
compared with Dex, consistent with better clinical
outcomes, although a declining trend in mean GHS score
was observed in both arms
Patients receiving bortezomib demonstrated significantly
better mean GHS over the study compared with patients
receiving Dex, as well as significantly better Physical Health,
Role, Cognitive and Emotional Functioning scores, lower
Dyspnoea and Sleep symptom scores, and better FACT-Ntx
questionnaire scores
SUMMIT58,59,63,64 Open-label, multi-centre, phase II trial of bortezomib in
patients with refractory MM (n¼ 202, 193 evaluated)
Change in HRQoL scores showed statistically significant
differences between response groups with HRQoL
improvement in patients with CR or PR, mostly stable scores
in patients with minor response or no change
Fifteen HRQoL parameters were significant in predicting
mortality when univariate logistic regression was used.
When using multivariate regression with stepwise selection
to predict survival, only Fatigue and physical subscores were
significant predictors of survival
VISTA62,66,67 Randomised, open-label, multi-centre, phase III study to
compare VMP (n¼ 344) vs MP (n¼ 338) in NDMM patients
Clinically meaningful, transient HRQoL deterioration was
observed with VMP vs MP during early treatment (up to
cycle 4), followed by HRQoL improvements in VMP-treated
patients for all domains, relative to baseline/MP from cycle 5
onwards
Overall, mean scores improved in both arms by end-of-
treatment vs baseline. Among responding patients, mean
scores improved from time of response to end-of-treatment
assessment. Multivariate analysis showed a significant
impact of response duration or CR on GHS/Global HRQoL,
Pain and Appetite Loss. Analyses by bortezomib dose
intensity indicated better HRQoL in patients receiving lower
dose intensity
UPFRONT68–71 Randomised, open-label, multi-centre phase IIIb trial to
compare bortezomib with (i) Dex, (ii) Thal and Dex, or (iii)
VMP, followed by bortezomib maintenance in NDMM
patients (100 patients per arm)
A trend to decreased HRQoL score was observed in all
treatment groups during induction, followed by an increase
or stabilisation by the end of treatment
There were no differences between treatment arms during
induction. Moderate improvements were seen during
maintenance, except for Nausea/Vomiting and Diarrhoea
Abbreviations: CR, complete response; Dex, dexamethasone; GHS, Global Health Status; HRQoL, health-related quality of life; MM, multiple myeloma;
MP, melphalan and prednisone; NDMM, newly diagnosed multiple myeloma; PR, partial response; Thal, thalidomide; VMP, melphalan, prednisone and
bortezomib.
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interpret. The study did not present the mean HRQoL change from
baseline by cycle or domain. The speciﬁed analytical end point assessed
the change in HRQoL scores over time by comparing the change in scores
according to clinical response between baseline and the best clinical
response to treatment.58 This choice of ‘best end point’ for HRQoL analysis
rather than pre-determined data points throughout the trial is selective
and was not justiﬁed in the reporting.
HRQoL data from the VISTA phase III trial. The phase III VISTA trial was a
randomised, open-label, multi-centre study performed to assess VMP
(n¼ 344) vs MP (n¼ 338) treatment on overall survival and other clinical
beneﬁts in elderly patients with previously untreated MM and patients not
eligible for SCT.62,66,67 HRQoL was an exploratory end point of the VISTA
trial. Patients were followed up over 54 weeks (nine 6-week cycles) and
post treatment. The QLQ-C30 questionnaire was completed at screening,
on day 1 of each treatment cycle and every 8 weeks until progression
during follow-up (Table 1). A sustained HRQoL improvement was deﬁned
as a change in score of at least 5 points for at least two consecutive cycles
after best response, as described by Dubois et al.58 During early treatment
cycles, an overall deterioration in HRQoL was observed in VMP patients,
both vs baseline and MP-treated patients. At the cycle 4 assessment, mean
differences between the VMP and MP arms were deemed clinically
meaningful (X5 points) and statistically signiﬁcant (Po0.05) for all domain
scores, except for Cognitive Functioning, Nausea/Vomiting, and Dyspnoea.
From cycle 5 onwards, a general increase in all HRQoL domain scores was
reported in VMP-treated patients vs baseline and MP-treated patients
(Table 3).62
The VISTA trial also evaluated the impact of clinical response on HRQoL
across both treatment arms. Mean scores improved overall in responding
patients from time of response to end-of-treatment assessment, especially
in patients achieving CR. Multivariate analysis showed a signiﬁcant impact
of duration of response/CR on improving GHS/QoL, Pain, Appetite Loss and
Diarrhoea scores (Pr0.03 for all). Sustained HRQoL improvements of X5
points were seen following achievement of response.62
The impact of bortezomib dose on HRQoL was also evaluated in
VMP-treated patients at the time of, and one and two cycles before, both
best response and the end-of-treatment visit. Patients receiving a lower
dose intensity of bortezomib (o5.6mg/m2/cycle) for at least two cycles
before achieving overall response or before their end-of-treatment visit
generally reported better HRQoL vs the higher dose intensity group.62
Critical review of VISTA HRQoL data. The open-label VISTA study is to date
the largest randomised, multi-centre study in previously untreated, transplant-
ineligible MM patients reporting on HRQoL, with HRQoL collected as an
exploratory end point. HRQoL analyses were restricted to data collected from
baseline to the end-of-treatment visit, owing to low questionnaire completion
rates post-treatment. The results, however, demonstrated that HRQoL is not
compromised in the long term with VMP vs MP.
While the number of patients for whom HRQoL data were available and
comparable across the study, no between-group comparisons of patient and
disease characteristics or compliance rates were reported. This is important,
given that the authors did no imputation for missing data. Patients may drop
out of the study because of poor response or side effects, which may result in
overestimations of HRQoL scores.
Additional analysis investigated differences in HRQoL within treatment arms
using multivariate linear regression. The improvement in some HRQoL domains
identiﬁed after ‘best response’ may be inﬂuenced by the fact that HRQoL scores
for VMP patients were lowest at the point of CR, due to toxicity issues.
Exploratory, post hoc analyses by dose intensity provide some evidence
regarding the impact on HRQoL of bortezomib dose intensity. The VISTA study
authors acknowledged that the study was not designed to compare HRQoL
during the periods of twice-weekly and once-weekly bortezomib dosing, so the
evidence on higher HRQoL with lower dosages of bortezomib is preliminary.
Further studies will be required to conﬁrm a statistical relationship between
bortezomib dose intensity and HRQoL.
HRQoL data from the UPFRONT phase IIIb trial. In an ongoing randomised,
open-label, multi-centre clinical trial that compared the efﬁcacy and safety
of three bortezomib-based regimens in untreated, transplant-ineligible
NDMM patients, Niesvizky et al. described HRQoL data as a primary
objective from a total of 300 patients (100 patients per arm) who
completed the QLQ-C30 questionnaire. The phase IIIb UPFRONT study
compared the safety and efﬁcacy of VD with thalidomide and dexametha-
sone (VTD), and with melphalan and prednisone (VMP), followed by
bortezomib maintenance therapy (Table 3).68–71
Scores improved in all three treatment arms, except for Physical
Functioning, Role Functioning and GHS/QoL, which worsened in the VTD
arm.68–71 The observed data, linear mixed model estimates and sensitivity
analyses all showed a common trend to a transient decrease in HRQoL
during VD, VTD and VMP induction, followed by a subsequent trend to
improvement/stabilisation in HRQoL during single-agent bortezomib
maintenance.
A signiﬁcant worsening (reduction) (Po0.05) in mean GHS/QoL score at
cycle 7 from baseline was reported in the VTD and VMP arms (linear mixed
effect model). A sensitivity analysis used last observation carried forward
for patients with missing data, showing a signiﬁcant worsening from
baseline at cycle 7 in all bortezomib-based treatment arms (Po0.05).
Symptom scores changed very little during induction with all bortezomib-
based regimens, with moderate HRQoL improvements seen during
maintenance (except for Nausea, Vomiting and Diarrhoea).
Niesvizky et al. concluded that the trend to declining HRQoL
during induction may reﬂect the onset of treatment-associated
toxicity. Subsequent HRQoL improvement may reﬂect the positive
impact of achieving a response. The transient decline in HRQoL
observed in this study is similar to the trend previously reported in the
VISTA study.66
Critical review of UPFRONT HRQoL data. The UPFRONT data were
presented in abstract/poster format, which limits the scope for in-depth
critical evaluation. The trial design was open-labelled, but given the fact
that all patients received the investigational product, the potential for
enhanced response in patients who know that they are receiving an
investigational therapy can be excluded.
In terms of compliance, HRQoL assessments were available at baseline
and at least one post-baseline time point for 80% (VD), 67% (VTD) and 80%
(VMP) of patients. The information on compliance rates is fairly unspeciﬁc,
as it does not provide sufﬁcient information on overall compliance per
treatment cycle, and in particular during the maintenance phase.
The UPFRONT study authors concluded that post-induction improve-
ments/stabilisation in HRQoL may reﬂect the beneﬁcial impact of achieving
a response and the limited toxicity proﬁle associated with weekly
bortezomib maintenance. However, unhealthier patients may not have
completed HRQoL questionnaires at later stages of treatment, for example,
owing to neurotoxicity, leading to a potential bias in reporting.
For patients who died within the HRQoL evaluation period, missing
HRQoL assessments were assigned a score of zero, representing the worst
possible HRQoL score. While potentially exaggerating the HRQoL of
treatments that reduce mortality, this aspect is unlikely to have been a
major issue in this trial, given the similar survival rates observed.
Studies reporting on HRQoL in MM patients treated with
lenalidomide
Two studies reporting HRQoL data in MM patients treated with
lenalidomide were identiﬁed in the search, including comparisons of
MPR-R vs MPR vs MP in NDMM patients above the age of 65 (MM-015
trial),73–76 and lenalidomide plus high-dose dexamethasone in RRMM
patients (MM-018 trial).77–79 Key HRQoL results from these trials are
summarised in Table 4.
HRQoL data from the MM-015 phase III trial. The MM-015 phase III trial was
a multi-centre, randomised, double-blind, placebo-controlled, three-arm
parallel-group study to determine the efﬁcacy and safety of MPR-R
(n¼ 152) vs MPR (n¼ 153) and MP (n¼ 154) in NDMM subjects who are 65
years of age or older (Table 4). This study investigated HRQoL as a
secondary outcome at baseline and the beginning of every third cycle, and
at time of progression (PD) or discontinuation for reasons other than
progression (DC). HRQoL was assessed using the QLQ-C30 and QLQ-MY20
for the following pre-selected HRQoL domains: GHS/QoL, Physical
Functioning, Fatigue and Pain (QLQ-C30), and Side Effects of Treatment
and Disease Symptoms (QLQ-MY20) (Table 1).
In all three study arms, HRQoL improvement was observed from baseline to
study end for all speciﬁed HRQoL domains. Statistically signiﬁcant HRQoL
improvements (Po0.05) from baseline to cycle 10 (end of induction phase)
were observed in each domain for MPR-treated patients, with the exception
of Side Effects of Treatment (nonsigniﬁcant for all treatment arms).
Improvements in HRQoL in patients aged 65–75 years were comparable, or
slightly greater, to those in all patients aged X65 years.
Comparably favourable HRQoL results could not be replicated for the
subset of patients agedX75 years, owing to the limited number of patients.
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Changes in HRQoL from cycle 10 to cycle 16 were not statistically signiﬁcant
(P40.05) in any HRQoL domain, suggesting that the majority of
HRQoL improvement occurred during the induction phase and stabilised
during maintenance.76 With regards to changes from baseline at cycle 16,
there were statistically signiﬁcant changes in the MPR-R group for all domains
(again with the exception of Side Effects of Treatment), while statistically
signiﬁcant changes were not consistently observed for MPR and MP
patients.76
A mixed model repeated measures analysis for the QLQ-C30 and QLQ-MY20
scores indicated a signiﬁcant difference in changes in Physical Functioning
scores across treatment groups: scores improved signiﬁcantly (Po0.05) from
baseline in MPR-R and MPR patients but worsened in MP patients.76
Comparisons of HRQoL scores using trial- and domain-speciﬁc MIDs were
also conducted and time points at which mean changes from baseline for each
arm exceeded the MID were presented.75,76 In this study, the standard error of
measurement was used to establish MID.80,81 The MPR-R group mean change
from baseline exceeded the MID more frequently than was observed in the
other two treatment groups. MID HRQoL improvements were observed as early
as cycle 4 for Pain. MIDs were applied to investigate the percentage of patients
who had a change from baseline exceeding the MID at cycle 10 and 16 for
MPR-R and MP treatment groups. A higher number of patients in the MPR-R
group exceeded the MID for all domains.
An additional analysis presented results from a mixed-effects multiple
regression model that estimated which clinical parameters were associated with
statistically signiﬁcant and clinically meaningful improvements in HRQoL in the
MPR-R and MP treatment arms. More patients achieved very good partial
response or better (XVGPR) when receiving continuous MPR-R treatment than
those receiving MP. XVGPR was shown to improve GHS/QoL in a clinically
meaningful and statistically signiﬁcant way, suggesting that clinical responses
with MPR-R treatment were not related to HRQoL impairments due to
treatment-related toxicity. PD was also shown to negatively impact GHS/QoL
( 8.34; Po0.001), with MPR-R signiﬁcantly reducing the risk of PD vs MP.
Continuous MPR-R may therefore delay PD and help improve and maintain
HRQoL.74
Critical review of MM-015 HRQoL data. The percentage of patients
completing questionnaires until cycle 16 was consistently above a
threshold of 76%, with compliance rates above 65% at PD/DC. The
percentage of compliant subjects was not signiﬁcantly different between
treatment arms at any of the visits, except at cycle 7 for the QLQ-MY20
questionnaire (P¼ 0.036).76
Mean HRQoL domain scores were presented for each treatment at each
measurement time point, along with longitudinal differences between
treatment arms.
Signiﬁcant emphasis in the presentation of the ﬁndings, as reﬂected by
most reported comparative analyses between treatment arms, was placed
on ‘responder’ analyses (percentage of patients achieving a clinically
meaningful HRQoL response in each arm), using MID as the deﬁnition of
clinically meaningful response.
Patients randomised to MPR-R had worse HRQoL scores compared with
the other arms, but the difference was statistically signiﬁcant only for
Physical Functioning (P¼ 0.014). Sensitivity analyses and inclusion of
‘time arm’ interactions accounted for baseline differences. Mixed models
were used to estimate the treatment effect on HRQoL over time, adjusted
and unadjusted for baseline HRQoL scores.
The study used repeated measures mixed-effects modelling to account
for missing variables and described the extent of missing data overall and
by treatment arm. There were no statistically signiﬁcant differences in
demographics and disease-related characteristics between the three
treatment arms at baseline, cycle 10 or cycle 16, suggesting that there
was no signiﬁcant difference between treatment arms in patients who
dropped out or were non-compliant.
HRQoL data from the MM-018 phase III trial. In the MM-018 phase III
single-arm, open-label study, lenalidomide plus high-dose dexamethasone
was administered to 587 RRMM patients in the United Kingdom, Spain and
Ireland, to assess the safety of this regimen and its impact on HRQoL
(Table 4). Secondary outcome HRQoL assessments were conducted at
baseline and after 24 weeks of treatment using the QLQ-C30 and
QLQ-MY20 questionnaires (Table 1).
QLQ-C30 revealed no signiﬁcant median change (45 points MID) from
baseline in 14 of 15 domains for patients completing questionnaires at
baseline and 24 weeks. Median Fatigue increased in the United Kingdom/
Ireland population (score 11.1). QLQ-MY20 revealed no signiﬁcant median
change from baseline of all scores except an improvement in Future
Perspective in Spanish patients (median 11.1), for patients completing
questionnaires at baseline and 24 weeks.79 Alegre et al.77,78 reported
further HRQoL data from 63 patients enrolled in the Spanish cohort. At
week 24, 42 patients were available for HRQoL assessment. In addition to
the reported improvement in Future Perspective, a nonsigniﬁcant
impairment in the Physical Functioning domain of the QLQ-C30
functional scores was also observed (o5 points MID). The majority of
patients who experienced HRQoL changes according to QLQ-C30 and
QLQ-MY20 scores had clinically meaningful improvements in HRQoL,
regardless of response (20/42 patients achieved either a CR or VGPR
during treatment). Despite comedication with high-dose dexamethasone,
pre-existing neuropathy in 450% patients, prior MM treatment, and late
disease course, patients were able to maintain median QoL scores over
24 weeks.77–79
Critical review of MM-018 HRQoL data. The open-label, single-arm study
design did not allow for reliable inference on the extent to which
Table 4. Key results from lenalidomide clinical trials reporting HRQoL data
Trial/references Trial design Key HRQoL results
Lenalidomide
MM-01573–76 Phase III, multi-centre, randomised, double-blind,
placebo-controlled, three-arm parallel-group
study (MPR-R n¼ 152, MPR n¼ 153 or MP n¼ 154)
in NDMM patients X65 years
Clinically meaningful improvements in HRQoL were more
frequently observed in patients receiving MPR-R than those
receiving MP
The differences in HRQoL were most marked in terms
of Physical Functioning, and overall results were consistent
in patients aged 65 to 75 years
A higher percentage of MPR-R patients achieved the
MID in six pre-selected HRQoL domains than those receiving MP.
Improved or stabilising longitudinal HRQoL trends were
observed for most other HRQoL domains
MM-01877–79 Phase III, multi-centre, single-arm, open-label,
expanded-access study in RRMM subjects
(N¼ 587) treated with Lenþhigh-dose Dex in
4-week cycles. Subjects followed until PD or DC
In the Spanish cohort of the study, GHS/Global QoL, Fatigue,
Emotional Functioning, Physical Functioning, Role Functioning, Social
Functioning, Cognitive Functioning and Pain improved 45 points
Preservation of HRQoL correlated with response to treatment
in terms of Role Functioning, Emotional Functioning, Social
Functioning and Pain scores
Abbreviations: DC, discontinuation; Dex, dexamethasone; HRQoL, health-related quality of life; GHS, Global Health Status; Len, lenalidomide; MID, minimal
important difference; MM, multiple myeloma; MP, melphalan and prednisone; MPR(-R), melphalan, prednisone and lenalidomide (and maintenance
lenalidomide); NDMM, newly diagnosed multiple myeloma; PD, progressive disease.
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treatment truly impacts upon HRQoL. The data were collected at two end
points (baseline and week 24) and are therefore likely to be incomplete for
some patients (for example, 42/63 patients completed HRQoL at 24 weeks
in the Spanish subset). Unlike the APEX trial for bortezomib, no information
on missing data or withdrawals was reported. This may constitute a major
weakness especially among an RRMM population where missing data are
more likely to introduce potential bias.
CONCLUSIONS
To date, there has been a relatively small body of HRQoL data
published on novel MM treatments. Available HRQoL data do not
allow for comparisons of HRQoL impact across MM treatments,
owing to differences in patient population, lack of comparative
trials, differences in study designs and in methodology applied for
the speciﬁc HRQoL analysis.
Patient groups differ between trials, for example, in terms of age
distribution and pathology (NDMM or RRMM) being particularly
diverse, which may impact on HRQoL. Baseline HRQoL values were
signiﬁcantly different between treatment groups in the thalido-
mide HOVON49 and the bortezomib APEX trials. In cases where
baseline HRQoL results are statistically signiﬁcantly different
between treatment arms, it is important to conduct sensitivity
analyses in order to control for baseline differences in HRQoL, as
was done in the MM-015 trial.
Study design may also impact on interpretation of HRQoL
outcomes. Few studies were double-blind RCTs, such as the
lenalidomide MM-015 and thalidomide Waage et al. trials, making
inference for all other trials more difﬁcult. Unblinded studies (for
example, the thalidomide HOVON49 and all retrieved bortezomib
trials) may increase the potential for an enhanced response in
patients who are aware they are receiving an investigational
treatment. Even though a number of studies were open-labelled
(for example, thalidomide HOVON49 and Hjorth et al. trials, and
bortezomib APEX, VISTA and UPFRONT trials), their value in terms
of inference is superior to single-arm trials (for example,
bortezomib SUMMIT and lenalidomide MM-018 trials). Further-
more, some studies have only been reported as conference
proceedings (UPFRONT and extended analyses on clinical para-
meters affecting HRQoL in MM-015).
Differences in interpreting clinically meaningful MID thresholds
for MM were observed across retrieved studies. However, there is
no unanimous agreement on what constitutes clinically mean-
ingful MID changes per HRQoL domain, allowing for several
different deﬁnitions of MIDs as well as methods of analysis.
All retrieved studies explored HRQoL as pre-speciﬁed secondary
end points, except for the bortezomib UPFRONT study, in which
measurement of HRQoL changes is described as a primary
objective. RCTs measuring HRQoL as a primary outcome have
been shown to display higher concordance on pre-speciﬁed
quality measures.82 Consistent use of the well-validated QLQ-C30
and QLQ-MY20 questionnaires facilitates comparisons between
treatments. Of note, for individual treatment combinations
containing novel therapies, patterns in longitudinal HRQoL
trends are generally consistent across the majority of HRQoL
domains analysed. There are similarities between studies,
regarding timing of HRQoL assessments (Table 1), with common
time points at the beginning of treatment cycles. There have,
however, been inconsistent approaches to the analysis of HRQoL
data across studies in MM, and not all studies have reported the
observed HRQoL at each time point for all arms in the study,
which would constitute the most straightforward and transparent
way to present ﬁndings.
Differences in dealing with and reporting missing data were
observed across the retrieved studies. The thalidomide trials
retrieved in this analysis incorporated all data points at which
HRQoL was assessed and presented the observed results at all
time points. APEX and UPFRONT trials applied missing data
imputations but did not present these ﬁndings in detail. In
contrast, missing data imputations were not carried out in the
Table 5. Guidance in collecting and analysing HRQoL in MM patients treated with novel agents based on the current analysis
Instruments
 Internationally validated questionnaires, to be used in their entirety
 Questionnaires measuring the impact of treatment toxicity
 Prospective design
Study design
 Intention to treat principle
 Preferably randomised double-blind trial
 If study design is a randomised, open-label trial, baseline questionnaire to be completed before randomisation
Assessment time points:
 At baseline and at different pre-determined treatment time points
 At the end of treatment, ideally including a differentiation between disease progression and discontinuation
 Regular HRQoL assessments following end of treatment, if possible
Reporting and analysis
Compliance reporting:
 Compliance rates regarding questionnaire completion at each assessment time point and per study arm
 Statistical between-group comparisons at individual measurement time points, assessing data interpretability independent of absolute
compliance levels
 Between-group comparisons of individual patient categories (study drop-outs vs non-compliant vs compliant patients) in terms of patient
and disease characteristics and inclusion of treatment interaction terms
Types of HRQoL assessment:
 Longitudinal and cross-sectional analysis reporting of HRQoL
 Reporting of individual HRQoL scores at each time point and for each study arm
 Illustration of mean HRQoL changes from baseline over time via repeated measures analysis
 Illustration of both statistical significance and clinical meaningfulness (e.g., with MIDs)
Determination of MID should be based on a combination of statistical reasoning and clinical judgement,43 including both trial- and domain-
specific analyses
 Linear mixed model per treatment arm across all measurement time points
 Sensitivity analysis controlling for baseline HRQoL and baseline differences in key patient and disease characteristics
Abbreviations: HRQoL, health-related quality of life; MID, minimal important difference; MM, multiple myeloma.
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thalidomide Hjorth et al. trial, in the VISTA and SUMMIT trials for
bortezomib, or the MM-015 and MM-018 trials for lenalidomide.
However, results from MM-015 were strengthened through mixed
model repeated measures analyses. Mixed model repeated
measures analyses across time points and paired analyses of data
both between treatment arms at individual time points and
longitudinally within treatment arms across two time points are
methods of assuring that observed changes are not attributable to
the changing nature of the sample across time.
Differences in compliance rates between treatment arms, an
important pre-requisite for cross-sectional HRQoL data compar-
isons, were reported in the thalidomide Waage et al. and in the
lenalidomide MM-015 studies, but were not discussed in the other
trials.
Finally, in HRQoL analyses such as APEX, which assume a zero
HRQoL score for patients who have died, results may have
favoured bortezomib owing to the signiﬁcant survival beneﬁt
established in the study.
As some treatment options have prolonged survival in MM
patients, and owing to the impact of treatment-related toxicity on
HRQoL, HRQoL data have become increasingly relevant key
performance indicators. In the absence of differences in treatment
efﬁcacy, the choice of initial treatment should be based on HRQoL,
among other patient-related factors. Quality-adjusted survival
analyses that integrate HRQoL considerations may be important,
particularly in treatments that do not show signiﬁcant survival
advantages.83 Guidelines for best practice in collecting and
analysing HRQoL in MM would ensure that future data are more
useful in informing clinical decisions, whereby more consistent
reporting of HRQoL data will improve the understanding of the
HRQoL impact of different MM treatments. For those assessing
HRQoL in MM studies, our review provides guidance on good
practices and standardisation for HRQoL data collection, analysis
and reporting (Table 5). The proposed incorporation of HRQoL as a
clinically relevant end point in MM drug registration dossiers and
in RCTs stresses the need for validated instruments and speciﬁc
questionnaires, for instance to measure the impact of toxicities
such as peripheral neuropathy.37,84 Future HRQoL investigations in
MM patients would gain value if head-to-head comparative
studies were carried out.
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